Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Cladosporium herbarum* is a common filamentous fungus (mold) whose extract is utilized in clinical medicine as a biologic agent for the diagnosis and treatment of allergic respiratory diseases. As a significant aeroallergen, it is a frequent cause of fungal sensitization in patients with bronchial asthma and allergic rhinitis. In diagnostic settings, the allergen extract is used in skin prick tests (SPT) to identify specific IgE-mediated sensitivity. Therapeutically, it is employed in allergy immunotherapy (AIT), where it is administered in gradually increasing doses to induce immune tolerance and reduce the severity of allergic symptoms. Beyond its clinical use, *Cladosporium herbarum* is studied for its role in environmental health and its potential applications in bioremediation, such as the degradation of fungicides like imazalil in industrial effluents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cladosporium herbarum.